Difference Between TSI and TBII
TSI (thyroid-stimulating immunoglobulin) is a functional bioassay that specifically measures stimulating antibodies that activate the TSH receptor, while TBII (thyrotropin-binding inhibitory immunoglobulin) is a competitive binding assay that measures total TSH receptor antibodies—including both stimulating and blocking antibodies—making TSI more specific for detecting functionally active disease. 1
Key Mechanistic Differences
TBII (Thyrotropin-Binding Inhibitory Immunoglobulin)
- Assay type: Competitive binding/radioreceptor assay that measures inhibition of labeled TSH binding to TSH receptors
- What it detects: Total anti-TSH receptor antibodies (both stimulating AND blocking antibodies combined)
- Clinical implication: Cannot distinguish between stimulating antibodies (causing hyperthyroidism) and blocking antibodies (potentially causing hypothyroidism) 1
TSI (Thyroid-Stimulating Immunoglobulin)
- Assay type: Functional bioassay measuring actual cellular stimulation (cAMP generation)
- What it detects: Only the functionally stimulating antibodies that activate the TSH receptor
- Clinical implication: Directly reflects the pathogenic antibodies causing thyroid hyperfunction 1
Clinical Performance Comparison
TSI demonstrates superior diagnostic sensitivity and specificity compared to TBII:
- Sensitivity: TSI detects 95-100% of untreated Graves' disease patients vs. 84-89% for TBII 2, 3, 4
- Specificity: TSI shows higher specificity with better positive predictive value in clinical practice 2
- Detection threshold: TSI bioassay has 251-827 fold lower detection limits than TBII 5
Discordant Results Matter
When results differ between assays, the pattern is clinically informative 2:
- TBII positive/TSI negative: Only 42% have actual Graves' disease; 58% have other thyroid conditions (likely detecting non-pathogenic blocking antibodies)
- TSI positive/TBII negative: 89% have confirmed Graves' disease (detecting functionally relevant stimulating antibodies below TBII detection threshold)
Clinical Applications Where TSI Outperforms TBII
Disease Activity Assessment
TSI correlates more strongly with clinical disease activity 3:
- TSI shows stronger correlation with Graves' ophthalmopathy activity (r=0.83) and severity (r=0.81)
- 100% of patients with active Graves' ophthalmopathy are TSI positive vs. only 84% TBII positive
- All patients with diplopia from Graves' disease are TSI positive vs. 85% TBII positive
Treatment Response Prediction
TSI is an independent predictor of treatment outcomes while TBII is not 6:
- Higher baseline TSI levels independently predict poor response to immunosuppressive therapy (OR=1.086)
- TBII does not retain independent predictive value for treatment response
- TSI levels at antithyroid drug withdrawal predict relapse risk 7
Pregnancy Monitoring
Both antibodies cross the placenta, but their balance determines fetal outcome 1:
- TSI causes fetal/neonatal hyperthyroidism through direct thyroid stimulation
- The clinical impact depends on the balance between inhibitory (detected by TBII) and stimulatory (TSI) actions
- In practice, anti-TSH-R antibody levels >5 IU/L in the second trimester indicate risk for fetal thyroid dysfunction
Practical Clinical Recommendations
Use TSI when:
- Diagnosing euthyroid Graves' disease with ophthalmopathy (57% TSI positive vs. 41% TBII positive) 4
- Predicting treatment response or relapse risk 6, 7
- Evaluating severe ophthalmopathy or pretibial dermopathy (extremely high TSI indices in all cases) 4
- TBII results are equivocal or negative but clinical suspicion remains high
TBII remains acceptable for:
- Initial screening in straightforward hyperthyroid Graves' disease
- Pregnancy monitoring (standard practice uses anti-TSH-R antibody assays to identify at-risk fetuses) 1
Important Caveat
Age modifies diagnostic performance: Both antibodies show stronger correlation with disease activity in patients >45 years old (TBII-CAS: r=0.410; TSI-CAS: r=0.426), with higher diagnostic accuracy for identifying active disease in older patients 6.